International Pharmaceutical Social Risk Regulation: An Ethical Perspective

Cameron Gordon

    Research output: Contribution to journalArticle

    Abstract

    Pharmaceutical production and distribution constitute big business. For the companies the rewards can be substantial. Rates of return on drug company investments tend to be higher than many other manufacturing enterprises. But reward is only one side of the story. There is also the issue of social risk, the focus of this article. Social risk for pharmaceutical production is especially pronounced. An ineffective or, worse, dangerous drug, can have dire consequences for the population at large. For this reason, there is elaborate government regulation and oversight of drug safety and risk. These systems, especially in the US and Europe, will be the main focus of this paper. The two systems will be described, and then compared and contrasted in terms of their framing of social risk and actions governments take to limit it. Systems elsewhere, especially in the developing world, are increasing in relative importance and these will be briefly discussed as well. Ethical issues that have arisen in these various systems will be surfaced and analysed. The paper will close with some conclusions and suggestions for further research
    Original languageEnglish
    Pages (from-to)15-23
    Number of pages9
    JournalActa Pharmaceutica
    Volume61
    Issue number1
    DOIs
    Publication statusPublished - Mar 2011

    Fingerprint

    Pharmaceutical Preparations
    Reward
    Government Regulation
    Ethics
    Safety
    Research
    Population

    Cite this

    @article{7be89218ee794db08e35b6a3e2e54fbc,
    title = "International Pharmaceutical Social Risk Regulation: An Ethical Perspective",
    abstract = "Pharmaceutical production and distribution constitute big business. For the companies the rewards can be substantial. Rates of return on drug company investments tend to be higher than many other manufacturing enterprises. But reward is only one side of the story. There is also the issue of social risk, the focus of this article. Social risk for pharmaceutical production is especially pronounced. An ineffective or, worse, dangerous drug, can have dire consequences for the population at large. For this reason, there is elaborate government regulation and oversight of drug safety and risk. These systems, especially in the US and Europe, will be the main focus of this paper. The two systems will be described, and then compared and contrasted in terms of their framing of social risk and actions governments take to limit it. Systems elsewhere, especially in the developing world, are increasing in relative importance and these will be briefly discussed as well. Ethical issues that have arisen in these various systems will be surfaced and analysed. The paper will close with some conclusions and suggestions for further research",
    keywords = "Social Risk Regulation",
    author = "Cameron Gordon",
    year = "2011",
    month = "3",
    doi = "10.2478/v10007-011-0010-x",
    language = "English",
    volume = "61",
    pages = "15--23",
    journal = "Acta Pharmaceutica Jugoslavica",
    issn = "1330-0075",
    publisher = "Croatian Pharmaceutical Society",
    number = "1",

    }

    International Pharmaceutical Social Risk Regulation: An Ethical Perspective. / Gordon, Cameron.

    In: Acta Pharmaceutica, Vol. 61, No. 1, 03.2011, p. 15-23.

    Research output: Contribution to journalArticle

    TY - JOUR

    T1 - International Pharmaceutical Social Risk Regulation: An Ethical Perspective

    AU - Gordon, Cameron

    PY - 2011/3

    Y1 - 2011/3

    N2 - Pharmaceutical production and distribution constitute big business. For the companies the rewards can be substantial. Rates of return on drug company investments tend to be higher than many other manufacturing enterprises. But reward is only one side of the story. There is also the issue of social risk, the focus of this article. Social risk for pharmaceutical production is especially pronounced. An ineffective or, worse, dangerous drug, can have dire consequences for the population at large. For this reason, there is elaborate government regulation and oversight of drug safety and risk. These systems, especially in the US and Europe, will be the main focus of this paper. The two systems will be described, and then compared and contrasted in terms of their framing of social risk and actions governments take to limit it. Systems elsewhere, especially in the developing world, are increasing in relative importance and these will be briefly discussed as well. Ethical issues that have arisen in these various systems will be surfaced and analysed. The paper will close with some conclusions and suggestions for further research

    AB - Pharmaceutical production and distribution constitute big business. For the companies the rewards can be substantial. Rates of return on drug company investments tend to be higher than many other manufacturing enterprises. But reward is only one side of the story. There is also the issue of social risk, the focus of this article. Social risk for pharmaceutical production is especially pronounced. An ineffective or, worse, dangerous drug, can have dire consequences for the population at large. For this reason, there is elaborate government regulation and oversight of drug safety and risk. These systems, especially in the US and Europe, will be the main focus of this paper. The two systems will be described, and then compared and contrasted in terms of their framing of social risk and actions governments take to limit it. Systems elsewhere, especially in the developing world, are increasing in relative importance and these will be briefly discussed as well. Ethical issues that have arisen in these various systems will be surfaced and analysed. The paper will close with some conclusions and suggestions for further research

    KW - Social Risk Regulation

    U2 - 10.2478/v10007-011-0010-x

    DO - 10.2478/v10007-011-0010-x

    M3 - Article

    VL - 61

    SP - 15

    EP - 23

    JO - Acta Pharmaceutica Jugoslavica

    JF - Acta Pharmaceutica Jugoslavica

    SN - 1330-0075

    IS - 1

    ER -